TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: <100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: <100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: <100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: <100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: <100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: <100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: <100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: <100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: <100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: <100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: <100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: <100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: <100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: <100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: <100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: <100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: <100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: <100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: <100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: <100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: <100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 5.50E+3nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 5.50E+3nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 5.50E+3nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.420nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 1nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.370nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.370nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.370nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 1nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.380nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/RAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataKd: 0.380nMAssay Description:Table 8: Exemplary MEK inhibitor compounds (0, 0.01, 0.1, or 1 μM) were added to a 384-AlphaPlate (PerkinElmer, 6008350) by a digital liquid dis...More data for this Ligand-Target Pair